Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 6,100 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLDGet Free Report) CEO Bradley L. Campbell sold 6,100 shares of the firm’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $10.00, for a total value of $61,000.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Amicus Therapeutics Trading Up 1.4 %

Shares of NASDAQ FOLD traded up $0.14 during trading on Tuesday, reaching $10.31. The company had a trading volume of 1,173,053 shares, compared to its average volume of 2,798,164. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57. The company has a current ratio of 3.03, a quick ratio of 2.61 and a debt-to-equity ratio of 2.97. The business’s 50 day moving average price is $9.92 and its 200-day moving average price is $11.57.

Amicus Therapeutics (NASDAQ:FOLDGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. The firm had revenue of $110.40 million for the quarter, compared to analyst estimates of $111.19 million. Amicus Therapeutics had a negative return on equity of 77.08% and a negative net margin of 34.73%. The business’s quarterly revenue was up 27.9% compared to the same quarter last year. During the same period last year, the company earned ($0.18) EPS. As a group, research analysts forecast that Amicus Therapeutics, Inc. will post -0.12 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on FOLD. UBS Group dropped their price objective on Amicus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, May 10th. JPMorgan Chase & Co. dropped their target price on shares of Amicus Therapeutics from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, March 18th. Bank of America reduced their price target on shares of Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, May 10th. Guggenheim raised shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Tuesday, May 14th. Finally, Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a research note on Thursday, May 30th. They issued an “overweight” rating and a $18.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.57.

Check Out Our Latest Stock Report on FOLD

Institutional Trading of Amicus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Comerica Bank lifted its position in Amicus Therapeutics by 0.8% during the 4th quarter. Comerica Bank now owns 103,418 shares of the biopharmaceutical company’s stock valued at $1,468,000 after purchasing an additional 774 shares during the period. Van ECK Associates Corp lifted its holdings in Amicus Therapeutics by 23.1% in the fourth quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 873 shares during the period. Franklin Resources Inc. boosted its stake in Amicus Therapeutics by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company’s stock valued at $780,000 after acquiring an additional 1,258 shares during the last quarter. American International Group Inc. grew its holdings in Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock worth $2,004,000 after acquiring an additional 1,298 shares during the period. Finally, O Shaughnessy Asset Management LLC grew its holdings in Amicus Therapeutics by 25.3% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 15,243 shares of the biopharmaceutical company’s stock worth $185,000 after acquiring an additional 3,082 shares during the period.

About Amicus Therapeutics

(Get Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Featured Articles

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.